Cardiovascular care in cancer patients

  • Sílvia Álvares Editor-in-chief of Nascer e Crescer – Birth and Growth Medical Journal. Centro Hospitalar Universitário do Porto; Department of Pediatric Cardiology, Centro Materno-Infantil do Porto, Centro Hospitalar Universitário do Porto; Unit for Multidisciplinary Research in Biomedicine, Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto

References

Kleinmahon JA, Landeck BF. Evaluation and Long-Term Outcomes of Cardiac Toxicity in Paediatric Cancer Patients. In: Karen Wonders, Brittany Stout editors. Pediatric Cancer Survivors. Croatia; 2017. p. 65-78. doi:10.5772/67043.

Shankar SM, Marina N, Hudson MM, Hodgson DC, Adams MJ, Landier W, et al. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children’s Oncology Group. Pediatrics 2008; 121:e387-96.

de Ferranti SD, Steinberger J, Ameduri R, Baker A, Gooding H, Kelly AS, et al. Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement from the American Heart Association. Circulation 2019; 139:e603-34.

Children’s Oncology Group. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers, Version 5.0. Monrovia, CA: Children’s Oncology Group. October 2018. Disponível em: http:// www.survivorshipguidelines.org/.

Westerink NL, Nuver J, Lefrandt JL, Vrieling AH, Gietema JA, Walenkamp AME, et al. Cancer treatment induced metabolic syndrome: Improving outcome with lifestyle. Crit Rev Oncol Hematol. 2016; 108:128-36. doi:10.1016/j.critrevonc.2016.10.011.

Lipshultz SE, Adams MJ, Colan SD, Constine LS, Herman EH, Hsu DT, et al. Long‐term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation. 2013; 128:1927-95. doi:10.1161/CIR.0b013e3182a88099.

Ryan TD, Nagarajan R, Godown J. Cardiovascular Toxicities in Pediatric Cancer Survivors. Cardiol Clin. 2019; 37:533–44. doi:10.1016/j.ccl.2019.07.002.

I Diretriz Brasileira de Cardio-Oncologia Pediátrica da Sociedade Brasileira de Cardiologia. Arq Bras Cardiol. 2013; 100:1-68.

Armenian SH, Hudson MM, Mulder RL, Chen MH, Constine, LS, Dwyer M, et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of

Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2015; 16:e123–36. doi:10.1016/S1470-2045(14)70409-7.

Armstrong GT, Oeffinger KC, Chen Y, Kawashima T, Yasui Y, Leisenring W, Stovall M, et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol. 2013; 31:3673–80. doi:10.1200/JCO.2013.49.3205.

Wong FL, Bhatia S, Landier W, Francisco L, Leisenring W, Hudson MM, et al. Cost-effectiveness of the children’s oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure. Ann Intern Med. 2014; 160:672–83. doi:10.7326/M13-2498.

Wolf CM, Reiner B, Kühn A, Hager A, Müller J, Meierhofer C, et al. Subclinical Cardiac Dysfunction in Childhood Cancer Survivors on 10-Years Follow-Up Correlates with Cumulative Anthracycline Dose and Is Best Detected by Cardiopulmonary Exercise Testing, Circulating Serum Biomarker, Speckle Tracking Echocardiography, and Tissue Doppler Imaging. Front Pediatr. 2020; 8:123-34. doi:10.3389/fped.2020.00123.

Sieswerda E, Postma A, van Dalen EC, van der Pal HJH, Tissing WJE, Rammeloo LAJ, et al. The Dutch Childhood Oncology Group guideline for follow-up of asymptomatic cardiac dysfunction in childhood cancer survivors. Ann Oncol. 2012; 23:2191–98. doi:10.1093/annonc/mdr595.

Published
2020-06-26
How to Cite
Álvares, S. (2020). Cardiovascular care in cancer patients. NASCER E CRESCER - BIRTH AND GROWTH MEDICAL JOURNAL, 29(2), 75-77. https://doi.org/10.25753/BirthGrowthMJ.v29.i2.20440
Section
Editorial